Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.
With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.
Abera develops a pipeline of vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also explores applications in personalized immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 44 (489) kSEK Resultatet efter finansiella poster
The board of Abera Bioscience has decided to reorganize the company in order to facilitate financing and collaborations for the various vaccine projects. Abera develops
Årsstämma 2023 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 14 juni 2023. Årsstämman fattade följande beslut. Fastställande av resultat- och balansräkning Årsstämman
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.